

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number	09502283
Filing Date	2000-02-11
First Named Inventor	Sun Ai Raillard
Art Unit	1639
Examiner Name	Epperson, Jon D.
Attorney Docket Number	70123.210US

## **U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5824485		1998-10-20	Thompson et al	
	2	5783431		1998-07-21	Peterson et al	
	3	5756316		1998-05-26	Volker Schellenberger	
	4	5426039		1995-06-20	Wallace et al	
	5	4683202		1987-07-28	Kary B. Mullis	

If you wish to add additional U.S. Patent citation information please click the Add button.

## **U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

## **FOREIGN PATENT DOCUMENTS**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09502283
Filing Date	2000-02-11
First Named Inventor	Sun Ai Raillard
Art Unit	1639
Examiner Name	Epperson, Jon D.
Attorney Docket Number	70123.210US

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	9842727	WO	A1	1998-10-01	SRI International		<input type="checkbox"/>
	2	9522625	WO	A1	1995-08-24	Affymax Technologies N. V.		<input type="checkbox"/>
	3	9633207	WO	A1	1996-10-24	Glaxo Group Limited		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	ARNHELM ET AL., "Polymerase Chain Reaction," C&EN 36-47 (October 1990)	<input type="checkbox"/>
	2	BARRINGER ET AL., "Blunt-end and single-strand ligations by escherichia coli ligase: influence on an in vitro amplification scheme," Gene 89:117-122 (1990)	<input type="checkbox"/>
	3	BOTSTEIN ET AL., "Strategies and applications of in vitro mutagenesis," Science 229(4719):1193-1201 (September 1985)	<input type="checkbox"/>
	4	CARTER, PAUL, "Site-directed mutagenesis," Biochem J. 237:1-7 (1986)	<input type="checkbox"/>
	5	CARTER ET AL., "Improved oligonucleotide site-directed mutagenesis using M13 vectors," Nucleic Acids Research 13(12):4431-4443 (1985)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09502283
Filing Date	2000-02-11
First Named Inventor	Sun Ai Raillard
Art Unit	1639
Examiner Name	Epperson, Jon D.
Attorney Docket Number	70123.210US

6	CHENG ET AL., "Long PCR," Nature 369:684-685 (June 1994)	<input type="checkbox"/>
7	CRAMERI ET AL., "1020-Fold aptamer library amplification without gel purification," Nucleic Acids Research 21 (18):4410 (1993)	<input type="checkbox"/>
8	DESOUZA ET AL., "Atrazine Chlorohydrolase from pseudomonas sp. strain ADP: Gene sequence, enzyme purification, and protein characterization," Journal of Bacteriology 178(16): 4894-4900 (August 1996)	<input type="checkbox"/>
9	FRITZ ET AL., "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucleic Acids Research 16(14):6987-6999 (1988)	<input type="checkbox"/>
10	GUATELLI ET AL., "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication," Proc. Natl. Acad. Sci 87:1874-1878 (March 1990)	<input type="checkbox"/>
11	KRAMER, WILFRIED ET AL., "Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucleic Acids Research 16(14):7207 (1988)	<input type="checkbox"/>
12	KRAMER, WILFRIED ET AL., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucleic Acids Research 12(24):9441-9456 (1984)	<input type="checkbox"/>
13	KUNKEL, THOMAS A. ET AL., "Rapid and efficient site-specific mutagenesis without phenotypic selection," Methods in Enzymology 154:367-382 (1987)	<input type="checkbox"/>
14	KUNKEL, THOMAS A., "The efficiency of oligonucleotide-directed mutagenesis" in "Nucleic Acids and Molecular Biology," Eckstein and Lilley, eds. Springer Verlag, Berlin 2:124-135 (1988)	<input type="checkbox"/>
15	KWOH, ET AL., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format," Proc. Natl. Acad. Sci. USA 86:1173-1177 (February 1989)	<input type="checkbox"/>
16	LANDEGREN ULF ET AL., "A ligase-mediated gene detection technique," Science 241:1077-1080 (August 1988)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09502283
Filing Date	2000-02-11
First Named Inventor	Sun Ai Raillard
Art Unit	1639
Examiner Name	Epperson, Jon D.
Attorney Docket Number	70123.210US

17	NAKAMAYE, KAY L., ET AL., "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis," Nucleic Acids Research 14(24):9679-9698 (1986)	<input type="checkbox"/>
18	OSTERMEIER, MARC ET AL, "A combinatorial approach to hybrid enzymes independent of DNA homology," Nature Biotechnology 17:1205-1209 (December 1999)	<input type="checkbox"/>
19	SAYERS, JON R. ET AL., "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide," Nucleic Acids Research 16(3):803-814 (1988)	<input type="checkbox"/>
20	SAYERS, JON R. ET AL., "5'-3' exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis," Nucleic Acids Research 16(3):791-802 (1988)	<input type="checkbox"/>
21	SCHATZ, PETER J., "Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in escherichia coli," Biotechnology 11:1138-1143 (October 1993)	<input type="checkbox"/>
22	SMITH, PAUL A. ET AL., "A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in Escherichia coli," Nucleic Acids Research 26(6):1414-1420 (1998)	<input type="checkbox"/>
23	SMITH, MICHAEL ET AL., "In vitro Mutagenesis," Ann. Rev. Genet 19:423-62 (1985)	<input type="checkbox"/>
24	SOOKNANAN ET AL., "NASBA: A detection and amplification system uniquely suited for RNA," Biotechnology 13:563:564 (June 1995)	<input type="checkbox"/>
25	STEMMER ET AL., "Molecular breeding of viruses for targeting and other clinical properties," Tumor Targeting 4:1-4 (1999)	<input type="checkbox"/>
26	TAYLOR, JOHN ET AL., "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA," Nucleic Acids Research 13(24):8749-8764 (1985)	<input type="checkbox"/>
27	TAYLOR, JOHN ET AL., "The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA," Nucleic Acids Research 13(24):8765-8785 (1985)	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09502283
Filing Date	2000-02-11
First Named Inventor	Sun Ai Raillard
Art Unit	1639
Examiner Name	Epperson, Jon D.
Attorney Docket Number	70123.210US

28	VAN BRUNT, JENNIFER, "Amplifying genes: PCR and its alternatives," Bio/Technology 8:291-294 (April 1990)	<input type="checkbox"/>
29	WELLS, JAMES A. ET AL., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," Gene 34:315-323 (1985)	<input type="checkbox"/>
30	WU, DAN Y. ET AL., "Specificity of the nick-closing activity of bacteriophage T4 DNA ligase," Gene 76:245-254 (1989)	<input type="checkbox"/>
31	ZOLLER, MARK J. ET AL., "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors," Methods in Enzymology 100:468-500 (1983)	<input type="checkbox"/>
32	ZOLLER, MARK J. ET AL., "Oligonucleotide-directed mutagenesis: A simple method using two oligonucleotide primers and a single-stranded DNA template," Methods in Enzymology 154:329-350 (1987)	<input type="checkbox"/>
33	ZOLLER, MARK J. ET AL., "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," Nucleic Acids Research 10 (20):6487-6500 (1982)	<input type="checkbox"/>
34		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09502283
Filing Date	2000-02-11
First Named Inventor	Sun Ai Raillard
Art Unit	1639
Examiner Name	Epperson, Jon D.
Attorney Docket Number	70123.210US

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Sharon M. Fujita/	Date (YYYY-MM-DD)	2007-10-16
Name/Print	SHARON M. FUJITA	Registration Number	38459

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.